
Chronic lymphocytic leukemia- Pipeline Insight, 2024
Description
Chronic lymphocytic leukemia- Pipeline Insight, 2024
DelveInsight’s, “Chronic lymphocytic leukemia- Pipeline Insight, 2024” report provides comprehensive insights about 55+ companies and 60+ pipeline drugs in Chronic lymphocytic leukemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Chronic lymphocytic leukemia: Overview
Chronic lymphocytic leukemia (CLL) is a malignancy of CD5+ B cells that is characterized by the accumulation of small, mature-appearing neoplastic lymphocytes in the blood, bone marrow, and secondary lymphoid tissues, resulting in lymphocytosis, leukemia cell infiltration of the bone marrow, lymphadenopathy, and splenomegaly. The exact etiology of CLL is unknown. Genetic factors, rather than environmental factors, are the most likely cause of CLL. However, few known risk factors for CLL include occupational causes by exposure to certain chemicals, radiation exposure, and tobacco users. Reports of farmers working around rubber manufacturing industries and workers with exposure to benzene and heavy solvents have shown an increased risk of CLL.
The pathogenesis of CLL is a two-step process that leads to the clonal replication of malignant B lymphocytes. The first step is the development of MBL cells secondary to multiple factors such as antigenic stimulation, genetic mutations, and cytogenetic abnormalities. The second step is the progression of MBL to CLL by the further insult to B-cell clone, either due to additional genetic abnormalities or changes in the bone marrow microenvironment. B-cell antigen receptor (BCR) expression induces antigen-independent, cell-autonomous signaling, which is an important step in the pathogenesis of CLL.
In CLL, CD5+ B cells are continuously activated by mutations leading to MBL. The accumulation of genetic abnormalities in more mature B cells causes a clonal division of the neoplastic B-cell within the lymph nodes. In CLL/SLL, the most common abnormal physical examination findings are lymphadenopathy, which is seen in 50 to 90% of patients. Cervical, supraclavicular, and axillary lymph nodes are the most commonly affected sites. These increased B-cell lymphocytes eventually spill into the peripheral blood, leading to the detection of lymphocytosis on a CBC.
These neoplastic B cells escape apoptosis and continue to divide over time within the lymph nodes. They then infiltrate the spleen and bone marrow, causing splenomegaly and hypercellular bone marrow (on bone marrow biopsy). The splenomegaly leads to increase sequestration of RBCs and platelets, leading to anemia and thrombocytopenia by decreasing the RBCs and platelets. Patients are more susceptible to autoimmune hemolytic anemia (positive Coombs test) and autoimmune thrombocytopenia. These B cells eventually spread throughout the body, causing systemic symptoms such as fever, night sweats, unintentional weight loss, fatigue, and early satiety. Lack of functional B cells decreases the body's ability to produce antibodies for immune responses, leading to hypogammaglobinemia, which eventually leads to an increased risk of infection.
Skin is the most commonly affected non lymphoid tissue in patients with CLL. Leukemia cutis (skin lesions) mainly involve the face and manifest as papules, macules, plaques, ulcers, blisters, or nodules. A skin biopsy can help confirm the diagnosis of CLL. Nonspecific secondary cutaneous lesions may occur due to bleeding, vasculitis, and infection. Exaggerated reactions to insect bites have been reported in patients as well.
""Chronic lymphocytic leukemia- Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Chronic lymphocytic leukemia pipeline landscape is provided which includes the disease overview and Chronic lymphocytic leukemia treatment guidelines. The assessment part of the report embraces, in depth Chronic lymphocytic leukemia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chronic lymphocytic leukemia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence chronic lymphocytic leukemia R&D. The therapies under development are focused on novel approaches to treat/improve chronic lymphocytic leukemia.
This segment of the Chronic lymphocytic leukemia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Chronic lymphocytic leukemia Emerging Drugs
- Pirtobrutinib: Loxo Oncology
- Cirmtuzumab: Oncternal Therapeutics
- MS-553: MingSight Pharmaceuticals
- NX-2127: Nurix Therapeutics
- NX-5948: Nurix Therapeutics
Further product details are provided in the report……..
Chronic lymphocytic leukemia: Therapeutic Assessment
This segment of the report provides insights about the different Chronic lymphocytic leukemia drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Chronic lymphocytic leukemia
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Intravenous
- Subcutaneous
- Oral
- Intramuscular
- Molecule Type
- Monoclonal antibody
- Small molecule
- Peptide
- Product Type
Chronic lymphocytic leukemia: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Chronic lymphocytic leukemia therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging chronic lymphocytic leukemia drugs.
Chronic lymphocytic leukemia Report Insights
- Chronic lymphocytic leukemia Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing chronic lymphocytic leukemia drugs?
- How many chronic lymphocytic leukemia drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of chronic lymphocytic leukemia?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the chronic lymphocytic leukemia therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for chronic lymphocytic leukemia and their status?
- What are the key designations that have been granted to the emerging drugs?
- Loxo Oncology
- Oncternal Therapeutics
- MingSight Pharmaceuticals
- Nurix Therapeutics
- Starton Therapeutics
- TG therapeutics
- Bristol Myers Squibb
- Novartis
- Aprea Therapeutics
- AstraZeneca
- Genor Biopharma
- Incyte Corporation
- MorphoSys
- Astex Therapeutics
- Lava Therapeutics
- Celgene Corporation
- Pirtobrutinib
- Cirmtuzumab
- MS-553
- NX-2127
- NX-5948
- Lenalidomide
- Nivolumab
- Buparlisib
- Ublituximab
- APR-246
- Ceralasertib
- GB261
- MOR00208
- AT7519M
- Buparlisib
- LAVA-051
- JCAR017
Table of Contents
210 Pages
- Introduction
- Executive Summary
- Chronic lymphocytic leukemia: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Chronic lymphocytic leukemia– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- Pirtobrutinib: Loxo Oncology
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- Cirmtuzumab: Oncternal Therapeutics
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- NX-2127: Nurix Therapeutics
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Chronic lymphocytic leukemia Key Companies
- Chronic lymphocytic leukemia Key Products
- Chronic lymphocytic leukemia- Unmet Needs
- Chronic lymphocytic leukemia- Market Drivers and Barriers
- Chronic lymphocytic leukemia- Future Perspectives and Conclusion
- Chronic lymphocytic leukemia Analyst Views
- Chronic lymphocytic leukemia Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.